Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease Neuropharmacology. Date: (2014) Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease Neuropharmacology Date: (2013) The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease. Neuromolecular medicine Date: (2013) A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe/PS1ΔE9 mouse model of Alzheimer's disease. PloS one Date: (2013) 1H NMR metabolomics investigation of an Alzheimer’s disease (AD) mouse model pinpoints important biochemical disturbances in brain and plasma Metabolomics Date: (2013) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. The Journal of clinical investigation Date: (2012) The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. The Journal of Neuroscience Date: (2011) The novel GLP-1 analogue liraglutide has neuroprotective properties in a mouse model of Alzheimer's disease REGULATORY PEPTIDES Date: (2010) Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease. European journal of pharmacology Date: (2010) Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease EUROPEAN JOURNAL OF PHARMACOLOGY Date: (2010)